Indaptus reports partial response in Decoy20 monotherapy; raises $5.7M

Indaptus Therapeutics, Inc.

• Decoy20 monotherapy induced partial response (liver metastases reduction) in one urothelial cancer patient; later disease progression.
• 7 patients dosed in combination with tislelizumab; first 3 evaluable: 1 stable disease, 2 progression.
• Raised $5.7M gross proceeds from convertible notes converted to common stock and pre-funded warrants in July 2025.
• Monotherapy portion completed; initial combination safety cohort dosing ongoing, with initial data expected later in 2025.